{"prompt": "['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', '1: mean of EQ-5D-5L Score change between the Baseline and the Follow-Up at 6 months and 12', 'months for the CRFA group', '2: mean of EQ-5D-5L Score change between the Baseline and the Follow-Up at 6 months and 12', 'months for the HA injection group', 'Analysis of variance (ANOVA) with treatment as fixed effect and study center as block effect on changes', 'in the EQ-5D-5L Score between the Baseline and the Follow-Up at 6 months and 12 months separately', 'will be performed for the comparison of the CRFA with the HA injection groups.', 'Treatment by study center interaction may be examined using analysis of variance (ANOVA) with', 'treatment, study center and treatment by study center interaction effects on changes in the EQ-5D-5L', 'Score between the baseline and the Follow-Up at 6 months and 12 months in the model.', 'The GPE scale at the 6 month and 12 month visit will be calculated and compared between the two', 'treatment groups:', 'Ha: 1 # 2', 'Where:', '1: mean of GPE score at 6 months and 12 month for CRFA group', '2: mean of GPE score at 6 months and 12 month for the HA injection group', 'Analysis of variance (ANOVA) with treatment as fixed effect and center as block effect on the GPE score', 'at 6 months and 12 months separately will be performed for the comparison of the CRFA with the HA', 'injection groups.', 'Treatment by study center interaction may be examined using analysis of variance (ANOVA) with', 'treatment, study center and treatment by study center interaction on the GPE score at the Follow-Up at 6', 'months and 12 months in the model.', '12.7 SAFETY ANALYSES', '12.7.1 Safety Parameter', 'All adverse events that occur during the study will be recorded per the protocol definitions. An overall', 'adverse event rate will be summarized for both treatment groups.', 'Version #: 4.0', 'Page 42 of 62', 'Version Date: 28Mar19']['AVANOS', 'Genicular Nerve Lesion Study', 'Confidential', 'Protocol # 105-17-0001', '12.7.2 Method of Analysis', 'Adverse events occurring during the study will be tabulated by body system, severity, and Investigator', 'reported relationship to the study device. Any deaths or serious device associated AEs will be', 'summarized. From enrollment to follow up visit at 6 months, adverse events will be stratified by subjects', 'randomization assignment. After follow up visit at 6 months to follow up visit at 12 months (end of study),', 'adverse events will be stratified among subject status between CRFA, HA and Crossover.', '12.8 HANDLING OF MISSING DATA', 'For the primary outcomes using the full analysis set, last observation carried forward (LOCF) procedures', 'may be used to impute missing data. A sensitivity analysis will be performed to evaluate the effect of', 'assumption of imputation. For the secondary outcomes and safety analysis, missing data will not be', 'imputed.', '13', 'ETHICAL, ADMINISTRATIVE, AND REGULATORY OBLIGATIONS', '13.1', 'INDEPENDENT ETHICS COMMITTEE (IEC) OR INSTITUTIONAL REVIEW', 'BOARD (IRB)', 'The study protocol, ICF document(s) subject recruitment materials, and any amendments must be', 'submitted to and approved by the IRB/IEC prior to enrolling subjects. The IRB must be operating in', 'compliance with 21CFR Part 56.', '13.2 HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA)', 'In accordance with the Health Insurance Portability and Accountability Act (HIPAA) of 1996, the', 'Investigator must obtain authorization from the subject to use and/or disclose protected health information', '(PHI). HIPAA authorization may be obtained as part of the ICF or in a separate document. HIPAA', 'authorization must include:', 'A.', 'Identification of the parties that can use and disclose the PHI', 'B.', 'Identification of the parties to whom the PHI may be disclosed', 'C.', 'A meaningful description of the PHI', 'D.', 'A description of each purpose for the use and disclosure', 'E.', \"Information about the subject's rights related to the authorization\", 'F.', 'Information about the expiration of the authorization', 'G.', 'Instructions on how to revoke the authorization', 'H.', 'A statement about what may happen if the authorization is not signed', 'I.', 'A warning that once information has been released, it may be released again without further', 'authorization', 'Version #: 4.0', 'Page 43 of 62', 'Version Date: 28Mar19']\n\n###\n\n", "completion": "END"}